



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application: KAESEMEYER, Wayne H. Group Art Unit: 1617
Serial No.: 09/419,517 Examiner: Kim, J.
Filing Date: October 18, 1999 Docket No.: 98-092-US-C2 (old) 2-20-01
25795-4-2 (new)
Title: METHOD AND FORMULATION FOR TREATING VASCULAR DISEASE

Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, and in compliance with 37 C.F.R. § 1.56, the Applicant requests consideration of this Supplemental Information Disclosure Statement.

Compliance with 37 C.F.R. §1.97

Pursuant to 37 C.F.R. 1.97(c), this Statement is being filed *after* the mailing date of a first Office Action on the merits, but *before* the mailing date of either a Final Office Action under 37 C.F.R. 1.113 or a Notice of Allowance under 37 C.F.R. 1.311. Accordingly, enclosed is a check in the amount of \$180.00 covering the fee set forth in 37 C.F.R. 1.17(p) for consideration of this Statement.

Information Cited

Applicant hereby makes of record in the above-identified application the patents, publications and other information listed on the attached form PTO-1449. The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant hereby makes the following information of record in the above-identified application. Applicant brings to the Examiner's attention the existence of a number of applications, most of which correspond (e.g. are priority documents) to the items provided with

the attached PTO Form-1449, which appear to be assigned to The Brigham and Women's Hospital ("The Brigham"). However, Applicant brings to the Examiner's attention U.S. Serial No. 09/092,563 and U.S. Serial No. 09/273, 233 (both of which are assigned to The Brigham) which is not reflected in any patent or publication cited in the attached PTO Form-1449, but which should be made of record in the above-identified application. Although Applicant is aware of the existence of these applications, Applicant is unaware of the contents of these applications because the applications have neither issued nor published. Hence, a copy of such application cannot be provided at this time to the Examiner.

Applicant also brings to the Examiner's attention the existence of Applicant's copending applications:

<u>U.S. Serial No.</u>	<u>Filing Date</u>	<u>Status</u>
09/226,580	January 7, 1999	Pending
09/293,392	April 16, 1999	Pending
09/420,328	October 18, 1999	Pending
09/420,816	October 19, 1999	Pending
09/605,599	June 28, 2000	Pending

Remarks

It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed PTO Form-1449 be initialed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application; and
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

Pursuant to 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall

not be construed as an admission that the information cited in this Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).


By submitting this Information Disclosure Statement, Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Finally, it is requested that the Patent Office records be corrected to indicate a new "Attorney Docket No.". Please reference Attorney Docket No. 25795-4-2 in future communications relating to this file.

The Commissioner is hereby authorized to charge any additional fees not included in the enclosed communication to Deposit Account No. 02-2051, identifying our Docket No. 25795-4-2.

Respectfully Submitted,

BENESCH, FRIEDLANDER,
COPLAN & ARONOFF, LLP



Raymond A. Miller
Registration No. 42,891

2300 BP Tower
200 Public Square
Cleveland, Ohio 44114-2378
(216) 363-4417

January 5, 2001



1614
\$

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE **RECEIVED**

JAN 11 2001

In re application: KAESEMEYER

Group Art Unit: 1614

Serial No.: 09/419,517

Examiner: (not yet assigned)

TECH CENTER 1600/2900

Filing Date: October 18, 1999

Docket No.: 97-092-US-C2 (old)
25795-4-2 (new)

Title: METHOD AND FORMULATION FOR TREATING VASCULAR DISEASE

Cleveland, Ohio 44114-2378

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8*

I hereby certify that the enclosed papers are being deposited with the United States Postal Service with sufficient postage as "FIRST CLASS MAIL" in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

January 5, 2001

(Date)

Greg Kolocouris
(type or print name of person mailing paper) Reg. No. A-47,711

[Signature]
Signature

Documents included:

1. Information Disclosure Statement
2. PTO Forms 1449/with references cited
3. Return card
4. Check for \$180.00
5. IDS cover sheet
6. POA w/Revocation and copy of assignment

BEST AVAILABLE COPY